ADMA Biologics Inc (NASDAQ:ADMA) shares hit a new 52-week low on Monday . The stock traded as low as $2.03 and last traded at $2.03, with a volume of 84192 shares trading hands. The stock had previously closed at $2.24.

Separately, ValuEngine downgraded ADMA Biologics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.

The company has a debt-to-equity ratio of 0.87, a current ratio of 2.83 and a quick ratio of 1.99.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Friday, August 11th. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.29). The business had revenue of $3.40 million during the quarter, compared to analyst estimates of $3.52 million. ADMA Biologics had a negative net margin of 35.00% and a negative return on equity of 116.73%. equities analysts expect that ADMA Biologics Inc will post -2.24 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “ADMA Biologics Inc (ADMA) Reaches New 1-Year Low at $2.03” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/adma-biologics-inc-adma-reaches-new-1-year-low-at-2-03/1683557.html.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.